Orlynvah, a new drug for urinary tract infections, has been approved by the FDA, providing a new treatment option for patients with limited alternatives. The drug, a combination of sulopenem etzadroxil and probenecid, has shown effectiveness in treating uncomplicated UTIs in adult women. Clinical trials with over 3,800 participants demonstrated that Orlynvah works as well as traditional antibiotics like ciprofloxacin and amoxicillin. However, the drug is not effective for complicated UTIs. Common side effects include diarrhea, nausea, and headaches. Orlynvah is not recommended for patients with gout, hypersensitivity reactions to certain antibiotics, blood disorders, uric acid kidney stones, or those taking ketorolac tromethamine.
Source link
Alternative For Patients With Limited Antibacterial Treatment Options
